Valneva's Stock Bounces Nearly 3% Attempting to Recover from a Three-Month Slide
The Lyon-based biotech specializing in vaccines is regaining ground during the session, in a slightly bullish SBF 120. The stock is attempting a recovery after several weeks of decline, while still trading below all its moving averages.
The stock rebounds after breaking through its technical support at €2.21 on June 25
Valneva's stock is up 2.93% at €2.28 midday, ranking among the strongest gains in the SBF 120, which itself is up by 0.39%. This rebound follows a month marked by a 12.71% drop, and a 17.45% decline over three months. The stock had recently tested its support at €2.21, breached on June 25 following its annual general meeting.
The RSI at 43 remains neutral, indicating a decompression without signs of exhaustion. However, the price is still trading below all its moving averages, with a gap of -3.80% from the MM20 (€2.37) and -37.36% from the MM200 (€3.64), which highlights the extent of the multi-month deterioration. The next resistance is identified at €2.67.
A Deteriorated 2026 Trajectory Following the Revised Guidance Announced in May
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's rise occurs on a stock that has been weakened for several months. During the announcement of the first quarter 2026 results (on May 13, 2026), the company adjusted its annual revenue forecasts, now expected to be between €135 and €150 million. The management highlighted the focus on key strategic projects, while pointing out the decline in third-party product sales and unfavorable trends in travel vaccine adoption.
Over the past year, the stock has lost 5.08%, but the decline has been concentrated over the last three months. Sustained crossing of the MM20 at €2.37 would be the next technical marker to observe to confirm whether or not the recovery initiated during the session continues.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
